BioAtla Inc - Company Profile
Powered by 
All the sales intelligence you need on BioAtla Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how BioAtla Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with BioAtla Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
BioAtla Inc (BioAtla) is a biotech company that develops novel monoclonal antibody and cell-based therapeutics using proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO) platforms. The company's pipeline products candidate includes BA3011 (mecbotamab vedotin) targets undifferentiated pleomorphic sarcoma, non-small cell lung cancer; BA3021 (ozuriftamab vedotin) for melanoma, squamous cell carcinoma of the head and neck; BA3182 treat adenocarcinomas; BA3361 for multiple tumor types; and BA3071 (Evalstotug) treat melanoma, non-small cell lung cancer (NSCLC) and carcinomas. BioAtla is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
11085 Torreyana Road, San Diego, California, 92121
Website
www.bioatla.com
Telephone
1 858 5580708
No of Employees
41
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BCAB (NASD)
Revenue (2024)
$2.0M
-81.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
14.6%
(2024 vs 2023)
Market Cap*
$5.5M
Net Profit Margin (2024)
XYZ
-369.8%
(2024 vs 2023)
* As of and is in US$
BioAtla Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Bioatla |
| BA3011 (Mecbotamab Vedotin): | Conditionally Active Biologics |
| Undifferentiated Pleomorphic Sarcoma | Comprehensive Integrated Antibody Optimization |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In November, the company entered into agreements with an affiliate of Yorkville Advisors Global (Yorkville) and funds managed by of Anson Advisors Inc. |
| 2024 | Contracts/Agreements | In September, the company entered into a partnership with Context Therapeutics Inc to develop, manufacture, and commercialize BA3362. |
| 2024 | Regulatory Approval | In May, the company received approval from the U.S. Food and Drug Administration for its new drug application to evaluate BA3361 (CAB-Nectin-4) antibody-drug conjugate for the treatment of multiple tumor types. |
Competitor Comparison
| Key Parameters | BioAtla Inc | CytomX Therapeutics Inc | Chinook Therapeutics Inc | CerFlux Inc | Cogent Biosciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Diego | South San Francisco | Seattle | Birmingham | Waltham |
| State/Province | California | California | Washington | Alabama | Massachusetts |
| No. of Employees | 41 | 69 | 214 | - | 258 |
| Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jay M. Short, Ph.D. | Chief Executive Officer; Chairman | Executive Board | 2020 | 68 |
| Richard A. Waldron | Chief Financial Officer | Senior Management | - | - |
| Chris Vasquez | Controller; Secretary; Chief Accounting Officer; Senior Vice President-Finance | Senior Management | 2024 | 49 |
| Eric L. Sievers, M.D. | Chief Medical Officer | Senior Management | - | - |
| Michael Melnick | Vice President - Chemistry, Manufacturing and Controls | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer